Grey Wolf Therapeutics was the second company established within the MTM ecosystem. Initially just an idea—seeded by Tom and Kirsty McCarthy—it became the first in the ecosystem to secure VC investment. 

Formed in September 2017, Grey Wolf Therapeutics was part of the MTM ecosystem for over seven and a half years, officially transitioning to a standalone entity on June 30, 2025. Over this journey, MTM proudly supported Grey Wolf Therapeutics in raising more than £80M, successfully enabling the molecule's entry into the clinic across Australia and Europe. 

Now operating with a fully independent team, Grey Wolf Therapeutics continues its important work. The MTM team is immensely proud to watch this alumni company, to which we dedicated years of effort, progress a biotech asset from concept to clinic, with many patients now having received the drug. 

For more questions about Grey Wolf Therapeutics please visit their website.